HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: nigel bates who wrote ()	5/19/2000 7:35:00 AM
From: nigel bates	Read Replies (1) of 1022

May 19 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) signed a collaboration agreement with SmithKline Beecham (SB) under which SB will use Abgenix's XenoMouse(TM) technology to generate fully human monoclonal antibodies to an undisclosed target. In return, Abgenix will receive a research license payment and could receive additional fees and milestone payments plus royalties on future product sales by SB. SB will be responsible for products developed through the collaboration. ``Abgenix is pleased to be collaborating with SB, one of the world's leading pharmaceutical companies,'' said R. Scott Greer, chairman, president and chief executive officer of Abgenix. ``Acceptance of our XenoMouse human antibody technology continues to spread among pharmaceutical and biotechnology companies.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext